Welgene Biotech Co.,Ltd.
TWO: 6661.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Yi Xing Lin
- Employees
- 80
- Headquarters
- Taipei, Taiwan
- IPO year
- 2017
- Market cap
- NT$414.8M
- Website
- https://www.welgene.com.tw
Loading 6661…
Loading profile data…Frequently asked questions about 6661
What does Welgene Biotech Co.,Ltd. (6661.TWO) do?
Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable...
Where does 6661.TWO trade?
Welgene Biotech Co.,Ltd. (6661.TWO) trades on the Taipei Exchange.
What sector is 6661.TWO in?
Welgene Biotech Co.,Ltd. (6661.TWO) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Welgene Biotech Co.,Ltd.?
Yi Xing Lin is the chief executive officer of Welgene Biotech Co.,Ltd. (6661.TWO).
Where is Welgene Biotech Co.,Ltd. headquartered?
Welgene Biotech Co.,Ltd. is headquartered in Taiwan.
Does 6661.TWO pay a dividend?
Welgene Biotech Co.,Ltd. (6661.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6661.TWO go public?
Welgene Biotech Co.,Ltd. (6661.TWO) completed its initial public offering in 2017.